Treatment Updates in the Management of Biliary Tract Cancers

home / insights / treatment-updates-in-the-management-of-biliary-tract-cancers

Expert oncologists review the current treatment landscape of biliary tract cancers and consider how they would apply data from clinical trials to their own practice.

EP. 1: Overview of Biliary Tract Cancers and Diagnosis

Milind Javle, MD, MD Anderson Cancer Center;Laura W. Goff, MD

June 20th 2023

Expert oncologists Milind Javle, MD, and Laura Goff, MD, reflect on the subsets of biliary tract cancers and consider best practices in making an accurate diagnosis.

EP. 2: What is the Role of Biomarker Testing in Biliary Tract Cancers?

Milind Javle, MD, MD Anderson Cancer Center;Laura W. Goff, MD

June 20th 2023

Shared insight on the role of molecular testing in the diagnosis of biliary tract cancers and how it may inform the selection of optimal therapy.

EP. 3: Biliary Tract Cancers: Standard of Care Treatment Strategies

Milind Javle, MD, MD Anderson Cancer Center;Laura W. Goff, MD

June 27th 2023

Drs Javle and Goff review standard of care treatment strategies for the management of biliary tract cancer and discuss recent NCCN guideline updates for the combination of durvalumab + cisplatin + gemcitabine.

EP. 4: Chemoimmunotherapy in Biliary Tract Cancers: Data From TOPAZ-1

Milind Javle, MD, MD Anderson Cancer Center;Laura W. Goff, MD

June 27th 2023

Centering discussion on data from TOPAZ-1, Milind Javle, MD, and Laura Goff, MD, reflect on the value of chemoimmunotherapy combinations in biliary tract cancer management.

EP. 5: Other Clinical Trials With Chemoimmunotherapy in Biliary Tract Cancers

Milind Javle, MD, MD Anderson Cancer Center;Laura W. Goff, MD

July 4th 2023

Expert perspectives on the KEYNOTE-966 and IMbrave151 clinical trials and novel chemoimmunotherapy combination strategies in biliary tract cancers.

EP. 6: The Evolving Treatment Landscape of Biliary Tract Cancers

Milind Javle, MD, MD Anderson Cancer Center;Laura W. Goff, MD

July 4th 2023

Closing out their discussion on biliary tract cancers, Milind Javle, MD, and Laura Goff, MD, highlight current treatment guidelines and unmet needs as the landscape continues to evolve.